Patents by Inventor Linda Snyder

Linda Snyder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
    Publication number: 20240141037
    Abstract: The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Application
    Filed: March 8, 2023
    Publication date: May 2, 2024
    Inventors: Catherine CARRIERE, Michael Molloy, Jay Rothstein, Linda Snyder
  • ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
    Publication number: 20240067719
    Abstract: The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Application
    Filed: October 11, 2022
    Publication date: February 29, 2024
    Inventors: Michael MOLLOY, Jay ROTHSTEIN, Dov PECHENICK, Linda SNYDER, Gordon POWERS
  • ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
    Publication number: 20240018238
    Abstract: The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Application
    Filed: May 15, 2023
    Publication date: January 18, 2024
    Inventors: Michael MOLLOY, Jay ROTHSTEIN, Dov PECHENICK, Linda SNYDER, Gordon POWRS
  • Methods of Treating Prostate Cancer
    Publication number: 20240000766
    Abstract: Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
    Type: Application
    Filed: September 13, 2023
    Publication date: January 4, 2024
    Inventors: Marco Gottardis, Rebecca Hawkins, Linda A. Snyder, Douglas H. Yamada
  • Methods of Treating Prostate Cancer
    Publication number: 20230149380
    Abstract: Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
    Type: Application
    Filed: November 17, 2022
    Publication date: May 18, 2023
    Inventors: Marco Gottardis, Rebecca Hawkins, Linda A. Snyder, Douglas H. Yamada
  • Anti-human vista antibodies and use thereof
    Patent number: 11649283
    Abstract: The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: May 16, 2023
    Assignees: IMMUNEXT, INC., JANSSEN PHARMACEUTICALS, INC.
    Inventors: Michael Molloy, Jay Rothstein, Dov Pechenick, Linda Snyder, Gordon Powers
  • Methods of Treating Prostate Cancer
    Publication number: 20230098047
    Abstract: Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
    Type: Application
    Filed: November 17, 2022
    Publication date: March 30, 2023
    Inventors: Marco Gottardis, Rebecca Hawkins, Linda A. Snyder, Douglas H. Yamada
  • Methods of Treating Prostate Cancer
    Publication number: 20230078160
    Abstract: Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
    Type: Application
    Filed: November 17, 2022
    Publication date: March 16, 2023
    Inventors: Marco Gottardis, Rebecca Hawkins, Linda A. Snyder, Douglas H. Yamada
  • Anti-human vista antibodies and use thereof
    Patent number: 11603402
    Abstract: The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: March 14, 2023
    Assignees: ImmuNext, Inc., JANSSEN PHARMACEUTICAL NV
    Inventors: Catherine Carriere, Michael Molloy, Jay Rothstein, Linda Snyder, Gordon Powers
  • Anti-human vista antibodies and use thereof
    Patent number: 11603403
    Abstract: The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: March 14, 2023
    Assignees: ImmuNext, Inc., JANSSEN PHARMACEUTICAL NV
    Inventors: Isabelle Lemercier, Michael Molloy, Jay Rothstein, Linda Snyder, Gordon Powers
  • Anti-human VISTA antibodies and use thereof
    Patent number: 11525000
    Abstract: The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: December 13, 2022
    Assignees: IMMUNEXT, INC., JANSSEN PHARMACEUTICALS, INC.
    Inventors: Michael Molloy, Jay Rothstein, Dov Pechenick, Linda Snyder, Gordon Powers
  • ANTI-VISTA ANTIBODIES AND FRAGMENTS
    Publication number: 20220144954
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.
    Type: Application
    Filed: November 18, 2021
    Publication date: May 12, 2022
    Inventors: Linda Snyder, Gordon Powers
  • Methods of Treating Prostate Cancer
    Publication number: 20220071980
    Abstract: Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
    Type: Application
    Filed: November 16, 2021
    Publication date: March 10, 2022
    Inventors: Marco Gottardis, Rebecca Hawkins, Linda A. Snyder, Douglas H. Yamada
  • Methods of Treating Prostate Cancer
    Publication number: 20220071979
    Abstract: Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
    Type: Application
    Filed: November 16, 2021
    Publication date: March 10, 2022
    Inventors: Marco Gottardis, Rebecca Hawkins, Linda A. Snyder, Douglas H. Yamada
  • Anti-vista antibodies and fragments
    Patent number: 11242392
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: February 8, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Linda Snyder, Gordon Powers
  • Method of treating prostate cancer
    Patent number: 11207311
    Abstract: Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: December 28, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Marco Gottardis, Rebecca Hawkins, Linda A Snyder, Douglas H Yamada
  • Anti-Vista Antibodies And Fragments, Uses Thereof, And Methods Of Identifying Same
    Publication number: 20210347896
    Abstract: The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Compositions and methods of using anti-VISTA antibodies in combination with one or more antibodies that bind to immune checkpoint proteins are also provided.
    Type: Application
    Filed: May 20, 2021
    Publication date: November 11, 2021
    Inventors: Linda A. Snyder, Gordon Powers, Enrique Zudaire Ubani, Douglas Matthew Marvel
  • ANTI-VISTA ANTIBODIES AND FRAGMENTS
    Publication number: 20210318322
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of detecting VISTA.
    Type: Application
    Filed: March 18, 2021
    Publication date: October 14, 2021
    Inventors: Linda A. Snyder, Gordon Powers, Manuel Alejandro Sepulveda, John D. Alvarez
  • ANTI-VISTA ANTIBODIES AND FRAGMENTS, USES THEREOF, AND METHODS OF IDENTIFYING SAME
    Publication number: 20210171640
    Abstract: The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Methods of identifying anti-VISTA antibodies capable of eliciting certain biological responses are also included.
    Type: Application
    Filed: November 25, 2020
    Publication date: June 10, 2021
    Inventors: Linda A. Snyder, Gordon Powers, Enrique Zudaire Ubani, Douglas Matthew Marvel
  • Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
    Patent number: 11014987
    Abstract: The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Compositions and methods of using anti-VISTA antibodies in combination with one or more antibodies that bind to immune checkpoint proteins are also provided.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: May 25, 2021
    Assignee: Janssen Pharmaceutics NV
    Inventors: Linda A. Snyder, Gordon Powers, Enrique Zudaire Ubani, Douglas Matthew Marvel